开发一个优化CXCR4向的光学对
Daniel Kwon1,2, Ingrid Bloise1, Zhengxing Zhang1
1BC Cancer Research Institute, Vancouver, British Columbia, Canada; and.
概括
一种新的C-X-C化学受体4 (CXCR4) 向性,BL34,被开发用于癌症成像和治疗. 无论是[68Ga]Ga-BL34还是[177Lu]Lu-BL34,都显示出了放射治疗应用的前临床结果.
科学领域:
- 核医学就是核医学.
- 放射性药物化学 放射性药物化学
- 在瘤学瘤学.
背景情况:
- C-X-C 化学因子受体4 (CXCR4) 是各种癌症的目标.
- LY2510924是一种已知的CXCR4向.
- 新型放射性标记的开发正在进行中,以改进向和超神应用.
研究的目的:
- 开发和评估一种新的向CXCR4的放射性标记,BL34,用于潜在的放射性剂.
- 在临床前的地幔细胞淋巴瘤模型中评估BL34的成像和治疗疗效.
主要方法:
- 结构-活性关系研究被用来设计一种具有增强CXCR4结合的新型循环,BL34.
- BL34被放射性标记为Gallium-68 ([68 Ga]Ga) 用于PET成像和Lutetium-177 ([177 Lu]Lu) 用于SPECT成像和治疗.
- 在体内研究中,在携带地幔细胞淋巴瘤外移植的小鼠中进行了实验,包括PET/SPECT成像,生物分布和治疗疗效评估.
主要成果:
- 与LY2510924相比,优化的循环BL34在CXCR4结合方面呈现了3倍的改善.
- Ga-BL34在临床前成像中表现出高瘤对比度和特定吸收.
- [177Lu]Lu-BL34显示出有利的生物分布,瘤吸收率高,脏排泄速度快,导致治疗研究中的剂量依赖生存益处.
结论:
- BL34代表了一种新的CXCR4向药,具有出色的成像和治疗特性.
- [Ga]Ga-BL34和[Lu]Lu-BL34是作为CXCR4表达癌症的放射性治疗剂的临床翻译的有希望的候选者.
相关概念视频
DNA Base Pairing
33.2K
Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
33.2K
DNA Base Pairing
32.3K
32.3K
Sign Test for Matched Pairs
407
The sign test for matched pairs offers a robust method for comparing two paired samples, often for the effects of an intervention in one of them. This method is very useful in situations where the underlying distribution of the data is unknown. The test compares two related samples—often pre- and post-treatment measurements on the same subjects—to determine if there are significant differences in their median values.
To conduct the sign test, we first calculate the differences in...
To conduct the sign test, we first calculate the differences in...
407
VSEPR Theory and the Effect of Lone Pairs
53.1K
Effect of Lone Pairs of Electrons on Molecule Geometry
53.1K
Base-pairing and DNA Repair
93.4K
93.4K
Optimal Foraging
13.8K
How animals obtain and eat their food is called foraging behavior. Foraging can include searching for plants and hunting for prey and depends on the species and environment.
13.8K


